Can GLP-1 Drugs Curb Alcohol Cravings? Here’s What New Research Found

GLP-1 receptor agonists such as Ozempic and Wegovy have already reshaped the treatment of obesity and type 2 diabetes.

Now, a growing body of research suggests these medications may do something unexpected: help people drink less alcohol and reduce the risk of other substance use disorders.

Although they are not approved for treating addiction, scientists are increasingly exploring how these drugs affect the brain’s reward system, potentially curbing cravings for alcohol, nicotine, opioids and other addictive substances.

The findings have generated excitement, but experts stress that the evidence is still evolving and that larger clinical trials are needed before GLP-1 drugs can be recommended for addiction treatment.

WHAT ARE GLP-1 DRUGS?

GLP-1 receptor agonists mimic the naturally occurring glucagon-like peptide-1 hormone, which helps regulate blood sugar, slows stomach emptying and increases feelings of fullness. Initially developed for diabetes, they later became widely used for weight management because of their ability to suppress appetite.

Researchers now believe these medications also influence the brain’s reward circuitry by altering dopamine signalling, a pathway involved in cravings for food, alcohol and other substances.

CAN THEY HELP PEOPLE DRINK LESS?

Early research suggests they might.

Several human studies have reported that people taking GLP-1 medications tend to consume less alcohol than before treatment. Animal studies have produced similar findings, showing reduced intake of alcohol as well as nicotine, opioids and cocaine.

Observational research has also linked GLP-1 therapy with a lower likelihood of developing alcohol use disorder compared with similar patients who were not prescribed the medications.

WHAT DOES THE LATEST STUDY SHOW?

A 2026 study by researchers at the University of Texas at El Paso analysed health records from more than 142,000 people with obesity or type 2 diabetes. Around 20,000 participants had been prescribed GLP-1 medications.

Compared with those not taking the drugs, GLP-1 users had:

74% lower odds of developing alcohol use disorder
69% lower odds of opioid use disorder
68% lower odds of nicotine use disorder
75% lower odds of cocaine use disorder

The findings suggest GLP-1 medications may influence addiction-related pathways beyond their metabolic effects.

HOW MIGHT THEY WORK?

Scientists believe the drugs act on regions of the brain involved in reward, motivation and craving.

While dopamine centres such as the ventral tegmental area and nucleus accumbens have long been associated with addiction, newer research points to another region—the lateral septum—which contains abundant GLP-1 receptors.

Stimulating these receptors may reduce the brain’s response to rewarding stimuli, making cravings less intense and weakening the mental cues that often trigger substance use.

WHAT ARE THE LIMITATIONS?

Despite the encouraging findings, researchers caution that the evidence is not yet definitive.

The University of Texas at El Paso study was observational, meaning it found an association but could not prove that GLP-1 drugs directly prevented addiction. Randomised controlled trials are still needed to determine whether the medications truly reduce alcohol and substance use, identify who benefits most, and establish the safest treatment approach.

Side effects, high costs and limited access also remain important considerations, and not everyone responds equally to GLP-1 therapy.

THE BOTTOM LINE

GLP-1 medications are emerging as a promising area of addiction research, offering the possibility of addressing both metabolic disease and substance use through shared brain pathways.

However, they are not a proven treatment for alcohol or drug addiction, and experts advise against using them solely to reduce drinking outside medical supervision. Anyone considering GLP-1 therapy should discuss the potential benefits and risks with a healthcare professional.

If ongoing clinical trials confirm the early findings, these drugs could eventually become an important addition to the treatment of alcohol and other substance use disorders.